Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
473.6 GBX | +0.42% | +6.00% | -2.75% |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
04-19 | Peel Hunt starts NatWest and Barclays at 'buy' | AN |
Sales 2024 * | 1.84B 2.32B 184B | Sales 2025 * | 1.98B 2.49B 198B | Capitalization | 1.49B 1.87B 149B |
---|---|---|---|---|---|
Net income 2024 * | 64M 80.57M 6.4B | Net income 2025 * | 91M 115M 9.1B | EV / Sales 2024 * | 0.8 x |
Net cash position 2024 * | 8.12M 10.22M 812M | Net cash position 2025 * | 13.65M 17.18M 1.37B | EV / Sales 2025 * | 0.74 x |
P/E ratio 2024 * |
23.3
x | P/E ratio 2025 * |
15.8
x | Employees | 7,859 |
Yield 2024 * |
5.06% | Yield 2025 * |
6.01% | Free-Float | 94.58% |
Latest transcript on PageGroup plc
1 day | +0.42% | ||
1 week | +6.00% | ||
Current month | +6.14% | ||
1 month | -2.19% | ||
3 months | +5.90% | ||
6 months | +7.34% | ||
Current year | -2.75% |
Managers | Title | Age | Since |
---|---|---|---|
Nicholas Kirk
CEO | Chief Executive Officer | - | 31/12/22 |
Director of Finance/CFO | 52 | 30/06/06 | |
Kaye Maguire
LAW | General Counsel | - | 16/09/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marie Metayer
BRD | Director/Board Member | 64 | 31/08/17 |
Director of Finance/CFO | 52 | 30/06/06 | |
Karen Geary
BRD | Director/Board Member | - | 31/03/22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 746 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
14/05/24 | 473.6 | +0.42% | 763,092 |
13/05/24 | 471.6 | +0.55% | 221,672 |
10/05/24 | 469 | +3.17% | 357,140 |
09/05/24 | 454.6 | +2.85% | 524,706 |
08/05/24 | 442 | -1.07% | 333,857 |
Delayed Quote London S.E., May 14, 2024 at 04:35 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.75% | 1.86B | |
+9.18% | 3.37B | |
-6.87% | 2B | |
+17.64% | 683M |
- Stock Market
- Equities
- MPI Stock